



Salvarsan® – its chemical structure and influence on pharmaceutical medicine

Thursday, September 09, 2004

03:30 PM - 05:00 PM

Chairmen: U. Stilz, Frankfurt, Germany
U. Holzgrabe, Würzburg, Germany

Sponsors: German Chemical Society (GDCh)
German Pharmaceutical Society (DPhG)

Supported by an unrestricted grant by Aventis Pharma GmbH, Frankfurt/Main - Bad Soden (Germany)

| | | |
|------------------|---------------------------------------|---|
| 03:30 - 04:00 PM | K. Williams Macclesfield, UK | The influence of Paul Ehrlich's Salvarsan® on clinical trials and the British pharmaceutical industry |
| 04:00 - 04:20 PM | S. Riethmiller Lexington, USA | The history of Salvarsan® and recent spectroscopic investigations of its nitrogen analog |
| 04:20 - 04:30 PM | B.K. Keppler Vienna, Austria | Insights into the chemical structure of Salvarsan® |
| 04:30 - 05:00 PM | B. Nicholson Hamilton, New Zealand | The synthesis and composition of Ehrlich's Salvarsan® |